Published online Jun 6, 2022. doi: 10.12998/wjcc.v10.i16.5406
Peer-review started: September 16, 2021
First decision: December 17, 2021
Revised: February 9, 2022
Accepted: April 2, 2022
Article in press: April 2, 2022
Published online: June 6, 2022
Processing time: 258 Days and 21.4 Hours
Glomangiomatosis (also known as diffuse glomus tumor) is extremely rare, accounting for only 5% of glomus tumors. The prevalence of glomus tumors is only 2% of soft tissue tumors. Lesions can recur after resection. Although growth may be diffuse or infiltrating and invasive, definitive identifying standards for malignant glomus tumors are lacking. This article describes a case of glomangiomatosis with many nodular masses in the soft tissues of the right foot and calf. A review of the Chinese and English-language literature is included.
A case of glomangiomatosis in a 55-year-old Chinese woman who presented clinically with many nodular masses in the soft tissues of the right foot and calf. The tumor was examined histologically and immunostaining was performed.
Glomangiomatosis occurs most often in young people, in the distal extremities, but is rare. Multiple nodules are even rarer. Only 15 clinicopathological analyses of glomangiomatosis have been reported in the combined Chinese- and English-language literature. In the present case, microscopically, nested vascular globular cells were observed around the blood vessel wall. Immunohistochemistry revealed diffuse immunoreactivity for smooth muscle actin, vimentin, type IV collagen, and Bcl-2. Caldesmon, CD34, and calponin were weakly, partially, and slightly positive, respectively. There was no recurrence 1 year after resection.
Core Tip: We describe a case of glomangiomatosis with many nodular masses in the soft tissues of the right foot and calf, presented by a 55-year-old woman. Pigmented villous nodular synovitis was observed via imaging. Microscopically, nested vascular globular cells around the blood vessel wall were observed. After resection, there was no recurrence during the 1-year follow-up. Although growth may be diffuse or infiltrating and invasive, glomangiomatosis does not meet the identifying standards for malignant glomus tumors.